Stock listing

KRX:002630 Orientbio, Inc. (오리엔트바이오) 주가

Follow Orientbio, Inc. into a list and get an email when it puts out news.

Share price · KRX:002630

₩1,136.00 KRW -26.00 (-2.2%)

Close on Nov 20, 2026

Past year -6.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩1,136.00 – ₩1,179.00 KRWNov 20, 2026
Volume
17,690 sharesNov 20, 2026
Market cap
₩33.68B KRWAt the close on Nov 20, 2026 · price × 29.65M shares outstanding
52-week range
₩745.00 – ₩1,936.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩87.71M KRWMedian day 46,115 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Orientbio, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:002630 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩1,136.00-26.00-2.2%₩1,178.00₩1,179.00₩1,136.0017,690
₩1,162.00-27.00-2.3%₩1,188.00₩1,245.00₩1,074.0085,854
₩1,189.00-18.00-1.5%₩1,231.00₩1,231.00₩1,116.0047,632
₩1,207.00-70.00-5.5%₩1,277.00₩1,286.00₩1,200.00121,047
₩1,277.00+4.00+0.3%₩1,328.00₩1,328.00₩1,270.0020,256
₩1,273.00-13.00-1.0%₩1,273.00₩1,390.00₩1,260.0063,801
₩1,286.00-4.00-0.3%₩1,288.00₩1,314.00₩1,280.008,015
₩1,290.00+15.00+1.2%₩1,276.00₩1,297.00₩1,273.0024,528
₩1,275.00-38.00-2.9%₩1,365.00₩1,365.00₩1,229.0039,227
₩1,313.00-50.00-3.7%₩1,229.00₩1,352.00₩1,229.0057,436
₩1,363.00+166.00+13.9%₩1,227.00₩1,445.00₩1,185.00363,594
₩1,197.00+23.00+2.0%₩1,190.00₩1,221.00₩1,177.0021,064
₩1,174.00-36.00-3.0%₩1,189.00₩1,249.00₩1,151.0040,685
₩1,210.00+20.00+1.7%₩1,222.00₩1,225.00₩1,155.0015,786
₩1,190.00-39.00-3.2%₩1,229.00₩1,263.00₩1,170.0031,053
₩1,229.00-59.00-4.6%₩1,250.00₩1,300.00₩1,209.0044,959
₩1,288.00-9.00-0.7%₩1,283.00₩1,330.00₩1,280.0020,174
₩1,297.00-26.00-2.0%₩1,270.00₩1,329.00₩1,269.0046,115
₩1,323.00-37.00-2.7%₩1,379.00₩1,382.00₩1,320.0029,290
₩1,360.00-19.00-1.4%₩1,379.00₩1,379.00₩1,346.0018,604
₩1,379.00-60.00-4.2%₩1,436.00₩1,438.00₩1,366.0083,253
₩1,439.00-37.00-2.5%₩1,435.00₩1,485.00₩1,431.0048,276
₩1,476.00-30.00-2.0%₩1,504.00₩1,542.00₩1,406.00175,241
₩1,506.00-2.00-0.1%₩1,450.00₩1,519.00₩1,450.0029,334
₩1,508.00-2.00-0.1%₩1,510.00₩1,562.00₩1,491.0050,958
₩1,510.00-85.00-5.3%₩1,575.00₩1,579.00₩1,502.0042,256
₩1,595.00+60.00+3.9%₩1,560.00₩1,636.00₩1,502.0099,054
₩1,535.00-67.00-4.2%₩1,510.00₩1,586.00₩1,494.00145,301
₩1,602.00-36.00-2.2%₩1,632.00₩1,647.00₩1,602.0034,946
₩1,638.00-21.00-1.3%₩1,690.00₩1,690.00₩1,631.0019,401
₩1,659.00-17.00-1.0%₩1,676.00₩1,699.00₩1,652.0024,072
₩1,676.00+36.00+2.2%₩1,668.00₩1,718.00₩1,630.0026,374
₩1,640.00+12.00+0.7%₩1,647.00₩1,657.00₩1,628.0027,445
₩1,628.00-14.00-0.9%₩1,611.00₩1,668.00₩1,611.0050,565
₩1,642.00-59.00-3.5%₩1,710.00₩1,710.00₩1,641.00113,919
₩1,701.00-92.00-5.1%₩1,793.00₩1,793.00₩1,685.0078,882
₩1,793.00-36.00-2.0%₩1,824.00₩1,824.00₩1,775.0061,302
₩1,829.00-26.00-1.4%₩1,813.00₩1,867.00₩1,813.0033,231
₩1,855.00+29.00+1.6%₩1,936.00₩1,936.00₩1,821.00184,192
₩1,826.000.000.0%₩1,826.00₩1,826.00₩1,826.000
₩1,826.00+913.00+100.0%₩1,826.00₩1,826.00₩1,826.000
₩913.00+73.00+8.7%₩840.00₩923.00₩810.00378,301
₩840.00-33.00-3.8%₩873.00₩873.00₩824.00113,148
₩873.00-6.00-0.7%₩860.00₩874.00₩850.0065,853
₩879.00-32.00-3.5%₩920.00₩924.00₩879.00123,812
₩911.00-11.00-1.2%₩930.00₩949.00₩906.0044,279
₩922.00-3.00-0.3%₩925.00₩926.00₩906.0030,558
₩925.00-12.00-1.3%₩937.00₩944.00₩900.0056,509
₩937.00+18.00+2.0%₩919.00₩951.00₩898.0059,790
₩919.00-24.00-2.5%₩930.00₩936.00₩917.0050,830
₩943.00-7.00-0.7%₩950.00₩985.00₩908.0079,008

Splits

3 splits since 2003 · KRX:002630 · every price before a split is adjusted for it

DayRatioWhat
1-for-2Consolidation
1-for-2.245Consolidation
5-for-1Split
Ticker
KRX:002630
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
KRX
Currency
KRW

What changed lately

Latest news

Orient Bio To Sell 9.4 Billion Won Of Own Shares

Dec 2, 2025

Closed ₩1,254.00 (-0.8%) on Dec 3, 2025

All Orientbio, Inc. news

Orientbio, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
1 in the last 12 months · 1 in all · newest Dec 2, 2025 · oldest 2025

Valuation

P/E 14.6× against a median of 19.3×: 2nd lowest of 4 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−₩4.40B KRW
P/E
14.6×
EV/sales
−0.1×
EV/EBITDA
−0.8×
Price/book
0.5×
Gross margin
22.6%
Operating margin
9.9%
Net margin
8.1%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Orientbio, Inc. · KRX:002630US$25.17M−US$3.29M14.6×−0.1×−0.8×0.5×8.1%0.0×n/a
Ikonisys SA · EURONEXT:ALIKOUS$26.75MUS$31.11Mn/a20.4×n/a1.3×−302.8%0.3×n/a
Interpace Biosciences, Inc. · OTC:IDXGUS$26.56MUS$23.63M1.2×0.6×21.0×1.1×58.1%0.0×-0.33
Microbix Biosystems Inc. · TSX:MBXUS$26.27MUS$25.96Mn/a2.4×n/a1.6×−31.7%0.3×0.03
Bioptic Inc. · TPEX:6850US$26.10MUS$22.55Mn/an/an/a2.0×n/a0.2×n/a
genOway SA · EURONEXT:ALGENUS$25.86MUS$38.95M25.4×1.7×8.7×1.1×4.4%0.7×n/a
Genesystem Co., Ltd. · KRX:363250US$24.68MUS$22.48Mn/a29.8×n/a2.8×n/a0.2×n/a
Clever Culture Systems Limited · ASX:CC5US$24.56MUS$25.41Mn/a8.3×n/a4.9×−48.4%0.4×n/a
CLEO Diagnostics Ltd · ASX:COVUS$24.50MUS$20.38Mn/an/an/a7.4×n/a0.0×n/a
C&R Research Inc. · KRX:359090US$24.01MUS$12.51M19.3×0.3×23.4×0.7×2.6%0.0×n/a
HLB Panagene Co. Ltd. · KRX:046210US$23.69MUS$6.19Mn/a0.6×n/a0.4×−22.3%0.0×n/a
Median of the othersUS$25.27MUS$23.09M19.3×2.0×21.0×1.4×−22.3%0.2×-0.15

Events

QuarterResultsShare move
Q4 2024Jun 27, 2024 · Before open−1.9%
Q3 2023Feb 13, 2023 · After close−0.3%

Open Events

Financials

Annual, in KRW

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue29.8B29.4B28.0B28.8B26.3B52.0B37.7B30.4B121.2B109.0B
Cost of revenue24.6B22.2B18.4B19.0B17.3B32.8B30.5B27.4B106.3B100.6B
Gross profit5.18B7.20B9.58B9.82B9.01B19.2B7.20B3.01B14.9B8.37B
Research and development732.6M1.00B1.95B1.80B2.59B2.65B1.41B655.3M2.00B1.16B
Selling, general and administrative3.39B3.86B3.79B3.01B2.50B3.49B4.84B6.40B6.64B6.36B
Operating income-4.13B-3.08B4.45B3.47B-3.78B2.31B-11.2B-9.23B-6.56B-9.29B
Depreciation and amortization2.20B1.95B2.68B3.09B3.93B4.69B4.92B8.08B7.30B6.66B
EBITDA-1.93B-1.12B7.14B6.56B144.8M7.00B-6.33B-1.16B733.5M-2.62B
Interest expense128.4M220.3M56.9M252.3M432.9M559.7M439.3M3.44B00
Income before tax-4.57B-13.2B12.9B-12.6B-3.36B-15.3B-11.6B-13.2B-16.2B-22.8B
Income tax-34.4M-150.8M02.07B
Net income-4.57B-13.2B12.9B-12.4B34.2B-15.3B-10.9B-19.5B-13.9B-19.1B
Earnings per share, basic-77.02-222.57217.11-209.56288.43-128.84-106.90-191.61-183.84-256.89

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents5.83B6.53B6.11B5.93B30.0B10.9B2.35B9.17B24.4B19.0B
Short-term investments26.9B26.0B35.1B29.5B29.1B800.0M801.0M901.5M12.6B2.02B
Receivables6.57B5.59B5.63B4.87B4.75B9.42B10.9B7.12B23.3B20.9B
Inventory2.44B4.20B3.65B5.24B4.35B5.93B8.10B10.0B31.3B28.6B
Current assets44.0B47.4B59.0B49.2B70.5B29.1B22.2B32.3B95.9B77.3B
Property, plant and equipment31.3B40.2B41.7B61.9B54.9B
Goodwill1.00K1.00K1.00K1.00K1.00K1.00K1.00K1.00K7.99B10.1B
Total assets81.6B84.8B97.0B81.1B105.0B71.5B72.1B84.1B190.0B172.6B
Accounts payable633.5M576.2M609.8M503.1M768.6M760.0M837.4M639.2M11.4B10.4B
Current liabilities5.62B4.21B4.21B3.89B13.6B15.2B11.4B14.9B90.5B56.7B
Long-term debt1.23B1.54B48.9M12.2B10.4B
Total debt7.40B8.11B7.22B8.25B64.1B51.7B
Total liabilities13.1B12.9B11.9B9.66B21.8B23.0B20.1B21.4B110.1B74.7B
Shareholders' equity68.5B71.8B85.1B71.4B83.2B48.5B52.0B64.8B52.7B70.3B
Shares outstanding59.3M59.3M59.3M59.3M118.6M118.6M101.8M101.8M75.4M74.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations2.60B752.3M3.76B1.16B2.35B8.74B-3.90B-11.5B-1.97B-5.11B
Capital spending-2.05B-4.79B-925.3M-485.6M-2.21B-256.2M-742.9M-16.1B-2.99B-5.28B
Free cash flow546.4M-4.04B2.83B674.3M140.5M8.48B-6.55B-30.0B-5.56B-10.4B
Cash from investing-4.03B-347.3M-26.7B-26.5B-5.10B
Cash from financing3.87B-2.58B23.0B33.9B20.8B
Share buybacks-10.0M9.58M9.58M
Change in cash-699.6M422.9M174.7M-24.1B19.1B8.59B-6.82B-15.3B5.43B10.6B

Open Financials

Cap table

Built by 6ix from Orientbio, Inc.’s releases

Common shares
29,645,751
Fully diluted
29,645,751

Fully diluted

LineShares
Common shares29,645,751

Share count over time

CountShares
Nov 22, 202629,645,751

Open Cap table

Log in to ask 6ix AI your own questions about Orientbio, Inc.